phrykt

AbCellera Biologics Inc. (ABCL): who owns it and who trades it

As of Nov 16, 2026, ABCL insiders reported 11 purchases worth $3.5M in the last 12 months. The largest buyer was Thermopylae Holdings Ltd. (10% owner), with $1.4M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AbCellera Biologics

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ABCL

151 funds and institutions reported ABCL shares worth $909M at the end of Q2 2026, about 38% of the company. The largest holder is Baker Bros. Advisors LP with 10.8%.

Funds and institutions (13F) 38%Everyone else 62%

10 largest owners, by share of the company

Baker Bros. Advisors LP10.8%
Capital World Investors4.4%
Two Sigma Investments, LP3.4%
TD Waterhouse Canada Inc.3.1%
Bank of America Corp2.0%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.4%
ArrowMark Colorado Holdings LLC1.3%
BlackRock, Inc.1.2%
Driehaus Capital Management LLC0.9%
Tudor Investment Corp Et Al0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP33.01M10.81%$259M+9%
Capital World Investors13.59M4.45%$107M+2%
Two Sigma Investments, LP10.44M3.42%$81.9M-1%
TD Waterhouse Canada Inc.9.57M3.13%$72.6MNo change
Bank of America Corp6.14M2.01%$48.2M+105%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC4.32M1.41%$33.9M-43%
ArrowMark Colorado Holdings LLC4.11M1.34%$32.2MNo change
BlackRock, Inc.3.81M1.25%$29.9M-6%
Driehaus Capital Management LLC2.86M0.94%$22.5M-29%
Tudor Investment Corp Et Al2.06M0.68%$16.2M-9%
Marshall Wace, LLP1.90M0.62%$14.9M+429%
UBS Group AG1.87M0.61%$14.7M-56%
Morgan Stanley1.67M0.55%$13.1M-25%
T. Rowe Price Associates1.59M0.52%$12.5M–
Citadel Advisors LLC1.59M0.52%$12.5M+17%
National Bank of Canada1.23M0.40%$9.7M–
Arrowstreet Capital, Limited Partnership1.04M0.34%$8.2M–
Renaissance Technologies LLC990,9290.32%$7.8M-34%
Counterpoint Mutual Funds LLC971,6430.32%$7.6M–
State Street Corp731,3620.24%$5.7M+0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ABCL insiders reported $3.5M of open-market purchases and $0 of sales.

Purchases, 12 months
$3.5M
11 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 13, 2026

Purchases and sales by month

$1.5M$1.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Andrew BoothCFOPurchase8,600$11.33$97.4KForm 4
Nov 12, 2026Thermopylae Holdings Ltd.10% ownerPurchase60,565$11.54$699KForm 4
Aug 24, 2026Michael R HaydenDirectorPurchase53,613$10.64$570KForm 4
Aug 18, 2026John S. MontalbanoDirectorPurchase10,000$11.03$110KForm 4
Aug 14, 2026Andrew BoothCFOPurchase37,200$10.32$384KForm 4
Aug 12, 2026Michael R HaydenDirectorPurchase46,387$10.37$481KForm 4
May 14, 2026John S. MontalbanoDirectorPurchase20,000$4.77$95.4KForm 4
Feb 27, 2026Thermopylae Holdings Ltd.10% ownerPurchase38,000$3.44$131KForm 4
Feb 27, 2026Andrew BoothCFOPurchase42,600$3.42$146KForm 4
Feb 26, 2026Thermopylae Holdings Ltd.10% ownerPurchase177,457$3.27$580KForm 4
Nov 26, 2025John S. MontalbanoDirectorPurchase50,000$3.57$178KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Thermopylae Holdings Ltd.10% owner$1.4M–Nov 12, 2026
Michael R HaydenDirector$1.1M–Aug 24, 2026
Andrew BoothChief Financial Officer$627K–Nov 13, 2026
John S. MontalbanoDirector$384K–Aug 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABCL short interest

Moderate short interest. 9.5% of ABCL shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 29.02M ABCL shares were sold short, 9.5% of the shares outstanding, down 6.2% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 8.5 trading days (days to cover).

Shares short, % of all shares

9.47%May 15Oct 3016.9%

Days to cover

8.5May 15Oct 3010.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202629.02M9.47%-6%3.42M8.5
Oct 15, 202630.93M10.09%-5%5.49M5.6
Sep 30, 202632.50M10.60%-4%5.43M6.0
Sep 15, 202633.93M11.07%-2%3.52M9.6
Aug 31, 202634.75M11.33%-16%6.71M5.2
Aug 14, 202641.34M13.48%-14%13.58M3.0
Jul 31, 202648.32M15.82%+7%5.00M9.7
Jul 15, 202645.11M14.77%-7%6.47M7.0
Jun 30, 202648.56M15.90%+8%9.11M5.3
Jun 15, 202644.91M14.71%-5%6.29M7.1
May 29, 202647.12M15.43%+10%8.45M5.6
May 15, 202642.95M14.06%-3%10.13M4.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

AbCellera Biologics company events

AbCellera Biologics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026AgreementAbCellera Biologics Inc. entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters relating to an underwritten public offering of (a) 17,435,897 shares of the Company’s common shares, no par value per share at a price… Filing
  3. Aug 10, 2026AnnouncementShared information with investors. Filing
  4. Aug 7, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jul 29, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Filing
  7. Jul 6, 2026LeadershipThe Board of Directors of AbCellera Biologics Inc. appointed Lynn Seely, M.D as a new Class III director. Filing
  8. Jun 17, 2026AnnouncementAbCellera Biologics Inc. issued a press release announcing a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. Filing
  9. Jun 12, 2026VoteReported shareholder vote results. Filing
  10. Jun 5, 2026LeadershipThe Board of Directors of AbCellera Biologics Inc. appointed Victor Sandor as a new director. Filing
  11. May 11, 2026ResultsReleased financial results. Filing
  12. Feb 24, 2026ResultsReleased financial results. Filing
  13. Jan 14, 2026AnnouncementShared information with investors. Filing
  14. Dec 18, 2025AnnouncementShared information with investors. Filing
  15. Nov 28, 2025AuditorThe Audit Committee of the Board of Directors of AbCellera Biologics Inc. approved the dismissal of KPMG LLP as the Company's independent registered public accounting firm, effective following the completion of KPMG's audit of the Company's consolidated financial statements for the fiscal year… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

AbCellera Biologics financials

Famous investors that hold ABCL

6 of the 50 well-known investors we track reported holding ABCL in their latest 13F filing. The largest position is Israel Englander's, worth $29.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.04M$29.7M0.0%+293%
Paul Tudor Jones · Tudor Investment CorpQ3 2026913,226$13.3M0.1%-56%
Ken Griffin · Citadel AdvisorsQ3 2026795,856$11.6M0.0%-50%
Jim Simons · Renaissance TechnologiesQ3 2026462,426$6.7M0.0%-53%
George Soros · Soros Fund ManagementQ3 2026150,000$2.2M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 2026136,181$2M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ABCL in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Carl L.G. Hansen13G/A19.7%
Nov 13, 2026Carl L.G. Hansen13G/A19.7%

Questions about AbCellera Biologics Inc. (ABCL) stock

Who owns the most ABCL stock?

The largest reported owner of AbCellera Biologics Inc. (ABCL) is Baker Bros. Advisors LP, with 10.8% of the company. In total, 151 funds and institutions reported holding ABCL at the end of Q2 2026, together about 38% of the shares. See the largest owners.

Are ABCL insiders buying or selling?

In the last 12 months, ABCL insiders reported 11 open-market purchases worth $3.5M and no sales. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in ABCL?

As of Oct 30, 2026, 29.02M ABCL shares were sold short, 9.5% of the shares outstanding, down 6.2% from the report before. At the average daily volume of 3.42M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.

Which famous investors hold ABCL?

6 of the 50 well-known investors we track reported ABCL in their latest 13F filing, including Israel Englander, Paul Tudor Jones, Ken Griffin. The largest position is worth $29.7M. See all holders.

Executive pay

AbCellera Biologics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, down 24% from $8.2M the year before. In the last 12 months, AbCellera Biologics's executives and directors bought $2.1M of stock on the open market and sold none.

Chief executive, total pay$6.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.